Cleantech Transit, Inc. (CLNO)
Cleantech Transit Inc. was founded to capitalize on technology advances and manufacturing opportunities in the growing clean energy public transportation sector. The Company has expanded its focus to invest directly in specific green projects. Recognizing the many economic and operational advances of converting wood waste into renewable sources of energy, Cleantech has selected to invest in Phoenix Energy (www.phoenixenergy.net). This project could benefit the Company’s manufacturing clients worldwide.
Cleantech Transit, Inc. (CLNO) is pleased to announce it has met its funding requirement to secure the Company’s ability to earn in 25% of the 500KW Merced Project.
The Company is in the final stages of closing its initial interest in the Merced Project and is currently working on completing the necessary documentation and expects closing the transaction soon. As previously announced Cleantech has the option to earn up to 40% of the Merced Project and the Company plans to continue to work towards increasing its interest in the Merced Project as they move ahead.
Biomass energy is also called renewable energy because the carbon dioxide which emerges out of the burning process goes into the atmosphere and absorbed by the plants, this also makes the photosynthesis process of the plants easy and the plants are the renewable source of energy as well. Many bio fuels products can be produced from agriculture and forest products. Products such as woods, pieces of woods, and straws, other plants roots and waste are also a source to produce biomass energy.
For more information about Cleantech Transit, Inc. visit its website www.cleantechtransitinc.com
Digimarc Corporation (Nasdaq:DMRC) reported financial results for the third quarter ended September 30, 2011. Revenues for the third quarter of 2011 increased 63% to $8.6 million from $5.2 million in the same quarter a year ago. The increase was primarily due to a 120% increase in license revenues. Operating income for the third quarter of 2011 totaled $1.4 million, an improvement of $2.2 million from an operating loss of $0.8 million in the same quarter a year ago. The increase primarily reflected higher licensing revenues, net of higher product development and marketing expenses associated with the launch of Digimarc Discover, as well as litigation expenses associated with the Verance dispute.
Digimarc Corporation provides media identification and management solutions to commercial entities and government customers in the United States and internationally.
Human Genome Sciences Inc. (Nasdaq:HGSI) announced financial results for the quarter ended September 30, 2011. reported revenues for the quarter ended September 30, 2011 of $34.0 million, compared with revenues of $50.8 million for the same period in 2010. Revenues included $18.8 million recognized from net sales of BENLYSTA and $12.0 million recognized from sales and deliveries of raxibacumab to the U.S. Strategic National Stockpile. The decrease in revenues reflected $36.1 million in upfront and milestone payments recognized from the ZALBIN� agreement with Novartis in the quarter ended September 30, 2010.
Human Genome Sciences, Inc. operates as a biopharmaceutical company. Its principal products in development include BENLYSTA for systemic lupus erythematosus; and raxibacumab for inhalation anthrax.
EDAP TMS SA (Nasdaq:EDAP) will take place on Wednesday, November 16, 2011, before the opening of the market. EDAP will hold a conference call on Wednesday, November 16, 2011 at 8:30 a.m. EST to discuss the results. The dial-in numbers are (877) 317-6789 for domestic callers and (412) 317-6789 for international. The conference ID number for both is 10005020. A live Webcast of the conference call will be available online from the investor relations page of the Company’s corporate Website at www.edap-tms.com.
EDAP TMS S.A., through its subsidiaries, engages in the development, manufacture, and marketing of minimally invasive medical devices primarily for urological diseases.
No comments:
Post a Comment